# Pembrolizumab as Neoadjuvant Treatment in HCC

> **NCT03337841** · PHASE2 · UNKNOWN · sponsor: **Kindai University** · enrollment: 50 (estimated)

## Conditions studied

- Hepatocellular Carcinoma

## Interventions

- **DRUG:** Pembrolizumab

## Key facts

- **NCT ID:** NCT03337841
- **Lead sponsor:** Kindai University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2017-11-10
- **Primary completion:** 2019-10-31
- **Final completion:** 2020-10-31
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2017-11-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03337841

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03337841, "Pembrolizumab as Neoadjuvant Treatment in HCC". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03337841. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*